InfuSystem provides FY2025 outlook: 8-10% revenue growth, high-teens AEBITDA margin

InfuSystem Holdings, Inc

TTM revenue to March 31, 2025: $137.6M; TTM adj. EBITDA $27.8M (leverage 0.98x).
Q1 2025 adj. EBITDA $6.3M (incl. $1.0M CEO severance) vs. $3.9M in Q1 2024.
FY2025 guidance: revenue growth 8-10% and adj. EBITDA margin in high teens % of revenue.
ERP upgrade: $0.7M spent in 2024, est. $2.5M in 2025; completion expected Q1 2026.
Share repurchases: $4.1M bought YTD under renewed $20M program (expires June 2026).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.